Abstract:Knowing the site of drug action is important to optimize effectiveness and address any side effects. We used light-sensitive drugs to identify the brain region-specific role of mGlu5 metabotropic glutamate receptors in the control of pain. Optical activation of systemic JF-NP-26, a caged, normally inactive, negative allosteric modulator (NAM) of mGlu5 receptors, in cingulate, prelimbic and infralimbic cortices and thalamus inhibited neuropathic pain hypersensitivity. Systemic treatment of alloswitch-1, an intrinsically active mGlu5 receptor NAM, caused analgesia, and the effect was reversed by light-induced drug inactivation in in the prelimbic and infralimbic cortices, and thalamus. This demonstrates that mGlu5 receptor blockade in the medial prefrontal cortex and thalamus is both sufficient and necessary for the analgesic activity of mGlu5 receptor antagonists. Surprisingly, when light was delivered in the basolateral amygdala, local activation of systemic JF-NP-26 reduced pain thresholds, whereas inactivation of alloswitch-1 enhanced analgesia. Electrophysiological analysis showed that alloswitch-1 increased excitatory synaptic responses in prelimbic pyramidal neurons evoked by stimulation of BLA input, and decreased feedforward inhibition of amygdala output neurons by BLA. Both effects were reversed by optical silencing and reinstated by optical reactivation of alloswitch-1. These findings demonstrate for the first time that the action of mGlu5 receptors in the pain neuraxis is not homogenous, and suggest that blockade of mGlu5 receptors in the BLA may limit the overall analgesic activity of mGlu5 receptor antagonists. This could explain the suboptimal effect of mGlu5 NAMs on pain in human studies and validate photopharmacology as an important tool to determine ideal target sites for systemic drugs.

What problem does this paper attempt to address?

This paper aims to explore and reveal the role and mechanism of type 5 metabotropic glutamate receptors (mGlu5 receptors) in specific regions of the brain in pain processing. Specifically, the study uses photosensitive drugs, especially the photocaged compound JF - NP - 26 and the photoswitchable compound alloswitch - 1, to identify the brain - region - specific role of mGlu5 receptors in pain control. These photosensitive drugs can be activated or inactivated by light of specific wavelengths, thereby achieving a high - degree of spatiotemporal control of mGlu5 receptor function without the need for genetic manipulation to target receptor proteins. The main findings of the study include: 1. **Photo - activation of JF - NP - 26**: In the cingulate gyrus, prelimbic cortex, medial prefrontal cortex, and thalamus, photo - activation of JF - NP - 26 inhibited the hypersensitivity of neuropathic pain. 2. **Systemic administration of alloswitch - 1**: Systemic administration of alloswitch - 1 (an intrinsically active negative allosteric modulator of mGlu5 receptors) led to an analgesic effect, and in the prelimbic cortex, medial prefrontal cortex, and thalamus, photo - induced drug inactivation reversed this effect. This indicates that the blockade of mGlu5 receptors in these regions is both sufficient and necessary for the analgesic activity of mGlu5 receptor antagonists. 3. **The role of the basolateral amygdala**: When light was delivered to the basolateral amygdala, local activation of systemically administered JF - NP - 26 decreased the pain threshold, while photo - inactivation of alloswitch - 1 enhanced the analgesic effect. Electrophysiological analysis showed that alloswitch - 1 increased the excitatory synaptic response of prelimbic pyramidal neurons induced by BLA input stimulation and decreased the feed - forward inhibition of amygdala output neurons by BLA. These effects were reversed after photo - silencing and reappeared after photo - re - activation. These findings are the first to demonstrate that the role of mGlu5 receptors in the pain neuraxis is not uniform, indicating that blockade of mGlu5 receptors in the basolateral amygdala may limit the overall analgesic activity of mGlu5 receptor antagonists. These results not only reveal the heterogeneous functions of mGlu5 receptors in different brain regions but also provide an important tool for the application of precision medicine, that is, to determine the ideal targets for systemic administration through photopharmacology, thereby optimizing treatment effects and reducing side effects.

A “double-edged” role for type-5 metabotropic glutamate receptors in pain disclosed by light-sensitive drugs

A 'double-edged' role for type-5 metabotropic glutamate receptors in pain disclosed by light-sensitive drugs

Enhancing Excitatory Activity of Somatosensory Cortex Alleviates Neuropathic Pain Through Regulating Homeostatic Plasticity

Alleviating pain hypersensitivity through activation of type 4 metabotropic glutamate receptor

Metabotropic Glutamate Receptor Subtype 1 and 5 Mediate Opposite Effects on Pain-Related Spatial and Temporal Synaptic Plasticity in Rat Hippocampal Formation:Multi-Electrode Array Recordings

Optogenetic and Chemogenic Control of Pain Signaling: Molecular Markers

Metabotropic Glutamate Receptor 5: A Potential Target for Neuropathic Pain Treatment.

Negative allosteric modulator of Group Ⅰ mGluRs: Recent advances and therapeutic perspective for neuropathic pain

Parallel Spinal Pathways for Transmitting Reflexive and Affective Dimensions of Nocifensive Behaviors Evoked by Selective Activation of the Mas-Related G Protein-Coupled Receptor D-Positive and Transient Receptor Potential Vanilloid 1-Positive Subsets of Nociceptors

Optical Control of Adenosine-Mediated Pain Modulation

Optogenetic Manipulations of Amygdala Neurons Modulate Spinal Nociceptive Processing and Behavior Under Normal Conditions and in an Arthritis Pain Model

A humanized chemogenetic system inhibits murine pain-related behavior and hyperactivity in human sensory neurons

An opioid efficacy switch for reversible optical control of peripheral analgesia

Characterization of New TRPM8 Modulators in Pain Perception

MrgC Agonism at Central Terminals of Primary Sensory Neurons Inhibits Neuropathic Pain

Counteracting Roles of Metabotropic Glutamate Receptor Subtypes 1 and 5 in Regulation of Pain-Related Spatial and Temporal Synaptic Plasticity in Rat Entorhinal–hippocampal Pathways

Peripheral group I metabotropic glutamate receptors modulate nociception in mice

Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain

Control of mechanical pain hypersensitivity in mice through ligand-targeted photoablation of TrkB-positive sensory neurons

Group II/III metabotropic glutamate receptors exert endogenous activity-dependent modulation of TRPV1 receptors on peripheral nociceptors

Metabotropic glutamate receptor subtype 8 in the amygdala modulates thermal threshold, neurotransmitter release, and rostral ventromedial medulla cell activity in inflammatory pain